Thank you, Mike, and good morning, everyone. Turning to the income statement on Slide 9. We started off the year on a strong note with another great performance by the ES segment. The positive demand trends that have underpinned 3 straight years of healthy revenue growth in this segment continued in Q1 as revenues across all 4 businesses in [indiscernible] were up from the prior year. Adjusted EBITDA of $230 million was above the expectations we provided on our Q4 call and up $15 million from a year ago. Our adjusted EBITDA margin in the quarter was 16.7%, up 20 basis points year-on-year and driven by the ES segment. Gross margin in the quarter was 29.5%, an increase of 80 basis points from a year ago. Within gross margin, we are seeing the benefit of our continued focus on pricing, greater productivity and operational efficiencies. SG&A expense as a percentage of revenue was 13.2% in Q1, which is slightly higher than the prior year's quarter. Some of that increase was acquisition-related as we absorbed some initial SG&A costs and incurred some incremental transaction-related severance costs as well as higher professional fees. We expect this percentage to improve in the upcoming quarters as we continue to manage SG&A headcount and further integrate the HEPACO and Noble Oil acquisition. For the full year 2024, we anticipate our SG&A expense as a percentage of revenue to be in the mid-12% range, which is consistent with prior year. Depreciation and amortization in Q1 came in at $95 million, up from a year ago due to our acquisitions. For 2024, we now expect depreciation and amortization in the range of $390 million to $400 million. Income from operations in Q1 was approximately $125 million, up slightly from the prior year. Q1 net income was $69.8 million, resulting in an earnings per share of $1.29. Turning to the balance sheet highlights on Slide 10. Cash and short-term marketable securities at quarter end were $443 million. In connection with the HEPACO and Noble transactions, we added $500 million in incremental debt to our term loan to finance those deals. Even with those additional borrowings, our balance sheet remains strong. We ended Q1 with total debt of $2.8 billion, a net debt-to-EBITDA ratio of 2.4x and continue to have no significant debt amounts coming due until 2027. Our weighted average pretax cost of debt at quarter end was 5.7%. Turning to cash flows on Slide 11. Cash provided from operations in Q1 was $19 million, reflecting our seasonally weakest quarter. CapEx, net of disposals, was $137 million, up significantly from prior year due to investments in our facilities network, including approximately $20 million for our Kimball expansion and $15 million for our Baltimore facility. In the quarter, adjusted free cash flow was a negative $118 million which was in line with our expectations. In addition to CapEx spend, this total reflects the timing of incentive comp payments, interest payments and working capital. For the full year 2024, we now expect our net CapEx to be in the range of $400 million to $430 million. This range includes the new additions of HEPACO and Noble Oil plus approximately $65 million to complete the construction of our Kimball incinerator and approximately $20 million for the purchase and expansion of the Baltimore facility. During Q1, we bought back approximately 27,000 shares of stock at a total cost of $5 million or an average price of approximately $183 a share. At March 31, we had $549 million remaining in our repurchase program. Moving to Slide 12. Based on our Q1 results, current market conditions and our recent acquisitions. We are raising our 2024 adjusted EBITDA to a range of $1.10 billion to $1.15 billion with a midpoint of $1.125 billion. This guidance assumes $30 million of contribution from HEPACO this year and approximately $5 million from Noble Oil. Looking at our annual guidance from a quarterly perspective, we are expecting Q2 adjusted EBITDA growth of 7% to 8% versus prior year. We expect ES to continue its upward trajectory, and SKSS should benefit from the rising base oil pricing environment to deliver growth versus prior year. We now expect this revised full year 2024 adjusted EBITDA guidance to translate to our segments as follows: In Environmental Services, we expect adjusted EBITDA in 2024 at the midpoint of our guidance to increase 10% to 12% from 2023; leveraging our network of assets, volume growth in our core lines of business, pricing strategies; the addition of HEPACO and multiple cost mitigation initiatives will drive this result. For SKSS, we expect full year 2024 adjusted EBITDA at the midpoint of our guidance to increase 6% to 8% from 2023. Given current market conditions and where we are today, we expect pricing to improve here in Q2 and into the back half. The promising initiatives that Mike outlined give us confidence that we can achieve this anticipated level of growth despite the slow start of the year. In our Corporate segment, at the midpoint of our guide, we expect negative adjusted EBITDA results to be 8% to 9% -- to be up 8% to 9% this year compared to 2023. More than half of that increase is additional costs from the acquired companies and related severance and integration costs. Looking at it as a percentage of revenue, we expect Corporate segment results to be flat to slightly down from prior year. For adjusted free cash flow, we continue to expect a range of $340 million to $400 million for 2024 or a midpoint of $370 million. If you take that midpoint and add that to Kimball and Baltimore spend, you arrive at adjusted free cash flow of $455 million, which is greater than 40% of our adjusted EBITDA expectations at the midpoint. In summary, Q1 was a great start to the year. We expect a favorable demand environment to support strong profitable growth throughout the remainder of this year. The ES segment has a healthy backlog of waste, a robust project pipeline, including PFAS opportunities and our services business all have good momentum. And we expect our SKSS segment to begin posting year-over-year growth this year. Overall, we look forward to the remainder of this year and continue to execute against our longer-term Vision 2027 goals. And with that, Christine, please open the call for questions.